141 related articles for article (PubMed ID: 25661917)
21. Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center.
Lourdudoss C; Vollenhoven Rv
Lupus; 2014 Mar; 23(3):299-304. PubMed ID: 24399811
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanisms of new immunosuppressants.
Halloran PF
Clin Transplant; 1996 Feb; 10(1 Pt 2):118-23. PubMed ID: 8680047
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic monitoring of mycophenolate mofetil.
Budde K; Glander P; Bauer S; Braun K; Waiser J; Fritsche L; Mai I; Roots I; Neumayer HH
Clin Chem Lab Med; 2000 Nov; 38(11):1213-6. PubMed ID: 11156363
[TBL] [Abstract][Full Text] [Related]
24. [Use of mycophenolate mofetil in kidney transplantation].
Hrvacevic R; Ignjatovic Lj; Vavic N
Vojnosanit Pregl; 2001; 58(4):415-9. PubMed ID: 11712223
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies.
Bandelier C; Guerne PA; Genevay S; Finckh A; Gabay C
Swiss Med Wkly; 2009 Jan; 139(3-4):41-6. PubMed ID: 19169902
[TBL] [Abstract][Full Text] [Related]
26. Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature.
Conti F; Ceccarelli F; Perricone C; Massaro L; Cipriano E; Pacucci VA; Truglia S; Miranda F; Morello F; Alessandri C; Spinelli FR; Valesini G
Immunol Res; 2014 Dec; 60(2-3):270-6. PubMed ID: 25468307
[TBL] [Abstract][Full Text] [Related]
27. Mycophenolate mofetil in pediatric renal transplantation.
Weber LT; Höcker B; Mehls O; Tönshoff B
Minerva Urol Nefrol; 2003 Mar; 55(1):91-9. PubMed ID: 12773970
[TBL] [Abstract][Full Text] [Related]
28. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review.
Mok CC
Scand J Rheumatol; 2007; 36(5):329-37. PubMed ID: 17963161
[TBL] [Abstract][Full Text] [Related]
29. Mycophenolate mofetil and neurological diseases.
Vermersch P; Stojkovic T; de Seze J
Lupus; 2005; 14 Suppl 1():s42-5. PubMed ID: 15803931
[TBL] [Abstract][Full Text] [Related]
30. Effect of mycophenolate mofetil monotherapy on T-cell functions and inosine monophosphate dehydrogenase activity in patients undergoing a kidney transplantation.
Kamar N; Glander P; Nolting J; Böhler T; Hambach P; Liefeldt L; Neumayer HH; Klupp J; Budde K
Transplant Proc; 2006 Sep; 38(7):2292-4. PubMed ID: 16980068
[TBL] [Abstract][Full Text] [Related]
31. Mycophenolate mofetil: An update.
Villarroel MC; Hidalgo M; Jimeno A
Drugs Today (Barc); 2009 Jul; 45(7):521-32. PubMed ID: 19834629
[TBL] [Abstract][Full Text] [Related]
32. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
33. Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats.
Ferjani H; El Arem A; Bouraoui A; Achour A; Abid S; Bacha H; Boussema-Ayed I
J Physiol Biochem; 2016 Jun; 72(2):133-44. PubMed ID: 26746208
[TBL] [Abstract][Full Text] [Related]
34. Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis.
Kazderova M; Jancova E; Rysava R; Merta M; Tesar V
Arch Med Res; 2008 Jan; 39(1):115-9. PubMed ID: 18068004
[TBL] [Abstract][Full Text] [Related]
35. A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan.
Hara R; Miyazawa H; Nishimura K; Momoi T; Nozawa T; Kikuchi M; Sakurai N; Kizawa T; Shimamura S; Yasuda S; Hiromura K; Sada KE; Kawaguchi Y; Tamura N; Takei S; Takasaki Y; Atsumi T; Mori M
Mod Rheumatol; 2015; 25(6):858-64. PubMed ID: 26215483
[TBL] [Abstract][Full Text] [Related]
36. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil.
Sanquer S; Breil M; Baron C; Dhamane D; Astier A; Lang P
Clin Pharmacol Ther; 1999 Jun; 65(6):640-8. PubMed ID: 10391669
[TBL] [Abstract][Full Text] [Related]
37. Mycophenolate mofetil in lupus glomerulonephritis.
Mok CC; Lai KN
Am J Kidney Dis; 2002 Sep; 40(3):447-57. PubMed ID: 12200794
[TBL] [Abstract][Full Text] [Related]
38. Perspectives on Mycophenolate Mofetil in the Management of Autoimmunity.
Bhat R; Tonutti A; Timilsina S; Selmi C; Gershwin ME
Clin Rev Allergy Immunol; 2023 Aug; 65(1):86-100. PubMed ID: 37338709
[TBL] [Abstract][Full Text] [Related]
39. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.
Simmons WD; Rayhill SC; Sollinger HW
Drug Saf; 1997 Aug; 17(2):75-92. PubMed ID: 9285199
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis.
Czock D; Rasche FM; Carius A; Glander P; Budde K; Bauer S; Keller F; von Müller L
J Clin Pharmacol; 2007 Jul; 47(7):850-9. PubMed ID: 17526858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
